Nanotechnology Now

Our NanoNews Digest Sponsors





Heifer International

Wikipedia Affiliate Button


android tablet pc

Home > Press > To Reach, Perchance to Kill the Cancer: A Soliloquy From Epeius Nanotechnologies Opposes That 'Sea of Troubles'

Abstract:
New Publication Reveals Tumor-targeted Gene Delivery in Clinical Remission

To Reach, Perchance to Kill the Cancer: A Soliloquy From Epeius Nanotechnologies Opposes That 'Sea of Troubles'

San Marino, CA | Posted on September 8th, 2010

Epeius Biotechnologies Corporation, a leader in the emerging field of targeted genetic medicine, reports the publication of a landmark paper in clinical oncology. Following up on its advanced U.S. Phase I/II clinical trials of Rexin-G in chemo-resistant metastatic pancreatic cancer (Molecular Therapy, 2010, 18: 435-441), which gained both Orphan Drug and FDA Fast Track Status, this new paper documents the molecular mechanisms-of-action of Rexin-G seen in the process of tumor eradication—revealing the "smoking gun" of precision, tumor-targeted killer gene delivery amidst a veritable "sea" of actively dying (apoptosing) tumor cells. Equally as important was the clinical finding that surgical oncologists were able to do more for cancer patients after the metastatic disease was brought under control by Rexin-G treatment.

Based on the adaptive Phase I/II study design, which included an FDA allowance for surgical intervention to be added to the treatment protocol in cases where repeated Rexin-G infusions had served to control the cancer and halt disease progression, the report describes the use of Rexin-G as both neoadjuvant therapy (before surgery) and as adjuvant therapy (after surgery) to prevent post-surgical spread and disease recurrence. Remarkably, the excised tumor(s) showed the process of Rexin-G accumulation within the tumors, as well as the molecular mechanisms of tumor cell destruction, with an unprecedented level of histological high-definition.

The landmark paper, published in the latest issue of Oncology Reports (Open Access, 24: 829-833, 2010) demonstrates the physical accumulation of the intravenous Rexin-G nano-medicine within the metastatic tumor prior to its surgical excision. It additionally reveals the selective accumulation of the Rexin-G nanoparticles on the surfaces of the target cells, i.e., pancreatic cancer cells and their proliferative vasculature, which is a distinctive property of the tumor-targeted nanotechnology platform. Using elegant immunohistochemistry to identify the process of active cell death (apoptosis) enforced by Rexin-G, the molecular mechanisms of precision tumor-targeting and selective cell death have never been more vividly displayed. It bears mentioning that the pancreatic cancer patient highlighted in this histological study is currently in surgical remission, with no new lesions during Rexin-G treatment and no disease recurrence going on six months after the Rexin-G / Surgical Excision / Rexin-G treatment combination.

####

About Epeius Biotechnologies
Epeius Biotechnologies Corporation is a privately held biopharmaceutical company that is bringing the latest advancements in genetic medicine to the cancer patient with the development and commercialization of its leading oncology products and its tumor-targeted delivery systems. Rexin-G is currently approved for the treatment of all chemotherapy-resistant solid tumors by the Philippine FDA.

To learn more about our lead products and/or our pipeline of proprietary biotechnologies, please visit us at www.epeiusbiotech.com.

For recent papers, expert reviews, clinical reports in oncology and molecular therapy, etc., see the "Publications" section.

For more information, please click here

Copyright © PrNewswire

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

Haydale Secures Exclusive Development and Supply Agreement with Tantec A/S: New reactors to be built and commissioned by Tantec A/S represent another step forward towards the commercialisation of graphene October 24th, 2014

QuantumWise guides the semiconductor industry towards the atomic scale October 24th, 2014

MEMS & Sensors Technology Showcase: Finalists Announced for MEMS Executive Congress US 2014 October 23rd, 2014

Nanoparticle technology triples the production of biogas October 23rd, 2014

Nanomedicine

NYU Researchers Break Nano Barrier to Engineer the First Protein Microfiber October 23rd, 2014

Iranian Scientists Apply Nanotechnology to Produce Surgery Suture October 23rd, 2014

RF Heating of Magnetic Nanoparticles Improves the Thawing of Cryopreserved Biomaterials October 23rd, 2014

Sopping up proteins with thermosponges: Researchers develop novel nanoparticle platform that proves effective in delivering protein-based drugs October 22nd, 2014

Announcements

Haydale Secures Exclusive Development and Supply Agreement with Tantec A/S: New reactors to be built and commissioned by Tantec A/S represent another step forward towards the commercialisation of graphene October 24th, 2014

QuantumWise guides the semiconductor industry towards the atomic scale October 24th, 2014

Advancing thin film research with nanostructured AZO: Innovnano’s unique and cost-effective AZO sputtering targets for the production of transparent conducting oxides October 23rd, 2014

Strengthening thin-film bonds with ultrafast data collection October 23rd, 2014

Nanobiotechnology

NYU Researchers Break Nano Barrier to Engineer the First Protein Microfiber October 23rd, 2014

Nanoparticle technology triples the production of biogas October 23rd, 2014

Mechanism behind nature's sparkles revealed October 22nd, 2014

‘Designer’ nanodevice could improve treatment options for cancer sufferers October 22nd, 2014

NanoNews-Digest
The latest news from around the world, FREE





  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More














ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project







© Copyright 1999-2014 7th Wave, Inc. All Rights Reserved PRIVACY POLICY :: CONTACT US :: STATS :: SITE MAP :: ADVERTISE